

Haematologica  
HAEMATOL/2016/154211  
Version 2

Second-line rituximab, lenalidomide, and bendamustine (R2B) in mantle cell lymphoma: a phase 2 clinical trial of the Fondazione Italiana Linfomi

Francesco Zaja, Simone Ferrero, Caterina Stelitano, Angela Ferrari, Flavia Salvi, Annalisa Arcari, Gerardo Musuraca, Barbara Botto, Michele Spina, Claudia Cellini, Caterina Patti, Anna M. Liberati, Claudia Minotto, Stefano A. Pileri, Manuela Ceccarelli, Stefano Volpetti, Antonella Ferranti, Daniela Drandi, Elisa Montechiarello, Marco Ladetto, James Carmichael, and Renato Fanin

Disclosures: J.C. is employed by Celgene. J.C. owns stock of Celgene. R.F. received honoraria from Celgene, Roche and Mundipharma; M.L. has received honoraria from Amgen, Celgene, Gilead, Mundipharma, Novartis, J&J, Roche, Roche Diagnostics, Spretum and Takeda; S.V. received honoraria from Teva Italy; F.Z. received honoraria from Celgene, Roche and Mundipharma. R.F. has consulting or advisory roles with Celgene and Roche; M.L. has consulting or advisory roles with Amgen, Celgene, Gilead, Mundipharma, Novartis, J&J, Roche, Roche Diagnostics, Spretum and Takeda; F.Z. has a consulting or advisory role with Celgene and Roche. S.P. has a consulting or advisory role with Takeda/Millennium. R.F. receives research funding from Celgene and Roche; S.F. receives research funding from Amgen, Celgene, Gilead, Mundipharma, Novartis, J&J, Roche, Roche Diagnostics, Spretum and Takeda; F.Z. receives research funding from Celgene and Roche. S.F. has served on speakers bureaux for Mundipharma, Celgene, Pfizer and Janssen; M.L. has served on speakers bureaux for Amgen, Celgene, Gilead, Mundipharma, Novartis, J&J, Roche, Roche Diagnostics, Spretum and Takeda. R.F. has received travel, accommodation or expenses from Celgene, Roche and Mundipharma; S.F. has received travel, accommodation or expenses from Mundipharma, Spectrum and Janssen; J.C. has received travel, accommodation or expenses from Celgene; S.V. has received travel, accommodation or expenses from Roche; F.Z. has received travel, accommodation or expenses from Celgene, Roche and Mundipharma. A.A., B.B., C.C., C.M., D.D., A. Ferranti, A. Ferrari, A.M.L., C.M., G.M., C.P., S.F., M.S., C.S., declare no competing financial interests.

Contributions: Contribution: A.A., B.B., C.C., J.C., D.D., A. Ferranti, A. Ferrari, S.F., A.M.L., C.M., G.M., C.P., S.P., F.S., M.S., C.S. and S.V. collected and assembled data. C.M., S.F., M.L., S.P. and F.Z. analyzed and interpreted data. R.F., M.L. and F.Z. contributed to conception and design. J.C., C.P., provided study material or patients. All authors contributed to writing the manuscript and final approval of it.